News

October 6, 2017October 6, 2017

FDA Opens the Door for People with Asthma to Use Antifungal Therapy Pulmazole

The U.S. Food and Drug Administration has agreed to Pulmatrix’s request to consider making the lung-fungus therapy Pulmazole (PUR1900) available to people with asthma in addition to people with allergic bronchopulmonary aspergillosis, or ... Read more

October 5, 2017October 5, 2017

Depression and Anxiety Influence Pulmonary Fibrosis Patients’ Quality of Life, Study Reports

Idiopathic Pulmonary Fibrosis, News

Depression and anxiety significantly influence the quality of life of people with idiopathic pulmonary fibrosis, although not their hospitalization or death rates, a study found. IPF patients are susceptible to ... Read more

October 4, 2017October 4, 2017

Europe Approves Tecentriq Therapy for Advanced or Metastatic NSCLC

Lung Cancer, News

Patients in the European Union who have advanced or metastatic non-small cell lung cancer (NSCLC) now can be treated with Roche’s Tecentriq (atezolizumab). According to the European Commission marketing authorization, ... Read more

October 3, 2017October 3, 2017

Baseball Legend, Country Singer to Join Renowned Scientists at Pulmonary Fibrosis Summit

Idiopathic Pulmonary Fibrosis, News

A New York Yankees legend and a country music singer will join renowned scientists in speaking at the Pulmonary Fibrosis Foundation’s international PFF Summit 2017 in Nashville, Nov. 9-11. Top physicians and researchers ... Read more

October 2, 2017October 2, 2017

Prometic Gets FDA Approval to Start Phase 2/3 Trial of PBI-4050 in IPF Patients

Idiopathic Pulmonary Fibrosis, News

Prometic Life Sciences announced that PBI-4050, its investigational therapy for idiopathic pulmonary fibrosis (IPF), has been cleared by the U.S. Food and Drug Administration (FDA) to enter a Phase 2/3 combination-treatment trial in the ... Read more

September 29, 2017September 29, 2017

Phase 2 Trial Shows Patara’s PA101 May Reduce Chronic Cough in IPF Patients

News

Phase 2 clinical trial data demonstrated that Patara Pharma‘s investigative anti-inflammatory drug PA101 has the potential to significantly reduce chronic coughing in patients with idiopathic pulmonary fibrosis (IPF). This finding ... Read more

September 28, 2017

Only About Half of Adults with Work-related Asthma Received Pneumococcal Vaccine, CDC Says

News

A new Centers for Disease Control and Prevention (CDC) study finds that adults with work-related asthmawork-related asthma have more severe symptoms than those with nonwork-related asthma and are particularly vulnerable ... Read more

September 27, 2017September 27, 2017

Collaboration Will Raise IPF Awareness, Reward Best Ideas for Improving Quality of Life

News

The American Lung Association and Three Lakes Partners will collaborate to increase awareness about idiopathic pulmonary fibrosis (IPF) and reward big ideas to improve patients’ quality of life. The partnership was announced ... Read more

September 26, 2017September 26, 2017

Keytruda Approved in Canada for Treatment of Metastatic NSCLC

News

Merck’s Keytruda (pembrolizumab) is now available as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) in Canada. Adults whose tumors express high PD-L1, along with a ... Read more

September 25, 2017September 25, 2017

Promising New Diagnostic Tool May Accurately Predict Survival of IPF Patients

News

The expression of 52 genes can accurately predict the survival of individual idiopathic pulmonary fibrosis (IPF) patients, a new study confirms. This could improve treatment approaches and aid in management ... Read more